^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    STAMP inhibitor

    Related drugs:
    3d
    ASCENdANT: Asciminib in HER2+ Breast Cancer Brain Metastases (clinicaltrials.gov)
    P1/2, N=42, Not yet recruiting, Duke University | Initiation date: Feb 2026 --> Jul 2026
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Herceptin (trastuzumab) • Scemblix (asciminib)
    10d
    CABL001L12101: Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL (2025-522019-40-00)
    P1/2, N=14, Not yet recruiting, Novartis Pharma AG
    New P1/2 trial
    |
    ABL1 (ABL proto-oncogene 1) • CD19 (CD19 Molecule)
    |
    ABL1 T315I
    |
    cytarabine • vincristine • Scemblix (asciminib)
    13d
    Asciminib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Case Series and Review of Emerging Evidence. (PubMed, Hematol Rep)
    Its greatest clinical value appears to lie in rational combination regimens, maintenance strategies, and bridging to definitive therapies rather than single-agent salvage. Emerging structural biomarkers and ongoing clinical trials are expected to further refine patient selection, sequencing, and optimal integration of asciminib, particularly in CNS-involved disease and post-CAR-T cell relapse.
    Journal • IO biomarker
    |
    ABL1 (ABL proto-oncogene 1)
    |
    ABL1 T315I
    |
    Scemblix (asciminib)
    15d
    Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP (clinicaltrials.gov)
    P2, N=50, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ABL1 (ABL proto-oncogene 1)
    |
    Scemblix (asciminib)
    16d
    ASC2ADHERE: A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany (clinicaltrials.gov)
    P=N/A, N=380, Not yet recruiting, Novartis Pharmaceuticals
    New trial
    |
    Scemblix (asciminib)
    18d
    Importance of five membered heterocyclic compounds in treatment of chronic myeloid leukemia by targeting various pathways. (PubMed, Future Med Chem)
    Several clinically relevant agents, including dasatinib, ponatinib, and asciminib, incorporate such heterocyclic frameworks, highlighting their therapeutic significance. This review explores the chemical diversity, molecular interactions, and therapeutic potential of five-membered heterocyclic compounds in CML. Overall, these scaffolds represent promising candidates for developing more effective and less toxic treatment strategies, improving long-term patient outcomes.
    Review • Journal
    |
    ABL1 (ABL proto-oncogene 1)
    |
    dasatinib • Iclusig (ponatinib) • Scemblix (asciminib)
    19d
    ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE) (clinicaltrials.gov)
    P2, N=45, Not yet recruiting, University Health Network, Toronto
    New P2 trial
    |
    ABL1 (ABL proto-oncogene 1)
    |
    ABL1 fusion
    |
    dasatinib • Scemblix (asciminib)
    20d
    Asciminib RMP Study (clinicaltrials.gov)
    P=N/A, N=600, Recruiting, Novartis Pharmaceuticals | N=100 --> 600 | Trial completion date: Jul 2025 --> Jun 2030 | Trial primary completion date: Jul 2025 --> Jun 2030
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Scemblix (asciminib)
    22d
    ASC4INDIA: Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation (clinicaltrials.gov)
    P4, N=85, Completed, Novartis Pharmaceuticals | Active, not recruiting --> Completed | Trial completion date: Nov 2026 --> Mar 2026 | Trial primary completion date: Nov 2026 --> Mar 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1)
    |
    ABL1 T315I
    |
    Scemblix (asciminib)
    1m
    Targeting leukemic stem and progenitor cells expressing different BCR::ABL1 levels: antileukemic activity of asciminib with or without TKIs. (PubMed, Front Pharmacol)
    We investigated the cytotoxic effects of ASC, alone or with imatinib (IM) or nilotinib (NIL), on committed progenitors and LSCs from CML patients expressing high or low BCR::ABL1 at diagnosis. When combined with IM or NIL, ASC restored TKI activity against LTC-ICs expressing high BCR::ABL1 transcripts, with the association of ASC and NIL reducing both LTC-IC division rates and LTC-IC-derived CFUs. These findings suggest that ASC, alone or with NIL, may target LSCs and improve outcomes in patients with high BCR::ABL1 expression at diagnosis.
    Journal
    |
    ABL1 (ABL proto-oncogene 1)
    |
    ABL1 T315I
    |
    imatinib • nilotinib • Scemblix (asciminib)
    1m
    AsterA: A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia (clinicaltrials.gov)
    P2, N=69, Recruiting, Korean Society of Hematology | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Scemblix (asciminib)